Accuray Incorporated (NASDAQ:ARAY) Stock Position Cut by Wellington Management Group LLP

Wellington Management Group LLP trimmed its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 21.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,821,279 shares of the medical equipment provider’s stock after selling 501,200 shares during the quarter. Wellington Management Group LLP owned about 1.84% of Accuray worth $5,154,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ARAY. Tower Research Capital LLC TRC raised its holdings in Accuray by 165.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,096 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 7,531 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Accuray in the fourth quarter valued at $29,000. First Eagle Investment Management LLC boosted its stake in Accuray by 5.3% during the fourth quarter. First Eagle Investment Management LLC now owns 959,508 shares of the medical equipment provider’s stock valued at $2,715,000 after buying an additional 48,583 shares in the last quarter. Heartland Advisors Inc. grew its holdings in Accuray by 0.3% during the fourth quarter. Heartland Advisors Inc. now owns 2,857,500 shares of the medical equipment provider’s stock worth $8,087,000 after acquiring an additional 9,700 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Accuray by 22.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 56,104 shares of the medical equipment provider’s stock worth $151,000 after acquiring an additional 10,264 shares in the last quarter. 64.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Joseph E. Whitters bought 50,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average cost of $1.54 per share, with a total value of $77,000.00. Following the completion of the transaction, the director now directly owns 511,053 shares in the company, valued at approximately $787,021.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.78% of the company’s stock.

Accuray Stock Performance

Shares of ARAY opened at $1.82 on Friday. The company has a debt-to-equity ratio of 4.05, a current ratio of 1.58 and a quick ratio of 0.78. The stock has a market capitalization of $180.62 million, a P/E ratio of -8.27 and a beta of 1.44. Accuray Incorporated has a 12-month low of $1.46 and a 12-month high of $4.30. The firm’s 50 day moving average is $1.77 and its 200-day moving average is $2.34.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, May 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.05). The company had revenue of $101.13 million for the quarter, compared to the consensus estimate of $114.60 million. Accuray had a negative return on equity of 44.46% and a negative net margin of 4.99%. During the same period in the prior year, the business earned $0.01 earnings per share. Equities research analysts anticipate that Accuray Incorporated will post -0.16 EPS for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.